Does filgotinib belong to the Jak inhibitor class of drugs?

Filgotinib (Filgotinib) belongs to the Janus kinase (JAK) inhibitor class of targeted drugs. This is a new class of small molecule immunomodulatory drugs. In the past few years, it has become an important breakthrough in the treatment of autoimmune diseases such as rheumatoid arthritis and ulcerative colitis. The JAK signaling pathway plays a central role in the immune system. It regulates the signal transduction of a variety of cytokines (such as IL-6, IFN, etc.), and these factors are often closely related to inflammatory responses and immune abnormalities. Figotinib selectively inhibits the activity of JAK1, thereby blocking the cascade of inflammatory signals, reducing the immune system's attack on self-tissue, and achieving the purpose of anti-inflammatory and alleviating symptoms.

Compared with early broad-spectrum JAK inhibitorsThe outstanding feature of filgotinib is its higher selectivity - it mainly acts on JAK1, but has weak inhibition on JAK2, JAK3 and TYK2. This property means it maintains efficacy while having relatively few side effects. For example, some JAK2-related adverse effects (such as anemia or neutropenia) are relatively mild with filgotinib treatment. In addition, the convenience of oral administration also results in better long-term patient compliance.

Currently, filgotinib has been approved for the treatment of patients with moderate to severe rheumatoid arthritis who have insufficient response to traditionalDMARDs. It is also approved for the treatment of ulcerative colitis in some areas. Studies have shown that it can significantly improve symptoms such as joint swelling, pain and limited movement, and can delay the progression of joint damage on imaging. With the expansion of clinical application, filgotinib is also exploring its potential for use in inflammatory diseases such as Crohn's disease and psoriatic arthritis.

Although the drug has not yet entered the Chinese market,JAK inhibitor drugs (such as tofacitinib, baricitinib, upadatinib, etc.) have been successively launched in China and included in medical insurance, showing the clinical importance of this class of drugs

Reference materials:https://go.drugbank.com/drugs/DB14845